NLRP3 and Parkinson disease: In a proof-of-concept experiment, the oral treatment with NLRP3 inhibitor MCC950 was able protect dopaminergic neurons from α-syn aggregates-induced activation of the inflammasome, improving the motor performance in a preclinical mouse model of PD, but due to patent problems MCC950 cannot be commercialized (Gordon et al., 2018).